Clinical evidence supports that bioidentical compounded semaglutide and tirzepatide deliver similar pharmacokinetic profiles and efficacy outcomes when dosed appropriately
When used appropriately and under medical supervision, they can support sustainable weight management as part of a broader health plan
No official guidance exists, but we can make reasonable projections based on Lilly's existing products and the competitive landscape
Proactive nutritional management is important at this dose
When it comes to people with obesity and without diabetes, the 2025 AACE guidelines recommend semaglutide and tirzepatide as first line over other drug classes for a variety of conditions, including those with prediabetes, type 2 diabetes, osteoarthritis, kidney disease, heart failure, fatty liver, cardiovascular protection, and sleep apnea